Novartis Ag (NVS) Cash & Equivalents (2009 - 2026)
Novartis Ag (NVS) recorded Cash & Equivalents of $400 million in Q3 2026, down 95.8% from $9.56 billion a year earlier and down 94.7% from the prior quarter.
Powered by 
Analysis
Novartis Ag (NVS) Cash & Equivalents (2009 - 2026) Analysis & Trends
At the end of FY2025, Novartis Ag reported Cash & Equivalents of $11.44 billion, down 0.2% from FY2024.
- Annual Cash & Equivalents has a five-year compound annual growth rate of 3.4% (FY2020 to FY2025).
- Across earlier years, Cash & Equivalents came in at $11.46 billion in FY2024 (-14.4%), $13.39 billion in FY2023 (+78.2%), $7.52 billion in FY2022 (-39.4%) and $12.41 billion in FY2021 (+28.5%).
- The Q3 2026 figure is the lowest quarterly Cash & Equivalents since Q2 2014.
- On a year-over-year basis, Cash & Equivalents rose in 1 of the last eight quarters, with an average decline of 21.2%.
- Peak year-over-year performance for Cash & Equivalents in the last five years was growth of 264.4% in Q1 2022, against a decline of 95.8% in Q3 2026 at the low end.
- Per Business Quant, the preceding three quarters came in at $7.62 billion (Q2 2026), $6.88 billion (Q1 2026) and $11.44 billion (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,222.16 Bn | 1,195.77 Bn | 20.46 Bn | 4.89 Bn |
| 2 | Johnson & Johnson | 663.22 Bn | 583.08 Bn | 17.30 Bn | 16.91 Bn |
| 3 | AbbVie | 515.27 Bn | 483.28 Bn | 13.12 Bn | 10.77 Bn |
| 4 | Merck | 363.06 Bn | 326.00 Bn | 13.19 Bn | 9.55 Bn |
| 5 | Novartis Ag | 315.76 Bn | 288.99 Bn | - | 400.00 Mn |
| 6 | Astrazeneca | 289.77 Bn | 263.66 Bn | 13.26 Bn | 7.94 Bn |
| 7 | Amgen | 249.67 Bn | 201.32 Bn | 7.58 Bn | 13.19 Bn |
| 8 | Gilead Sciences | 208.85 Bn | 183.96 Bn | 6.73 Bn | 6.44 Bn |
| 9 | Pfizer | 166.92 Bn | 114.28 Bn | 12.56 Bn | 1.82 Bn |
| 10 | Vertex Pharmaceuticals | 138.84 Bn | 110.83 Bn | 2.91 Bn | 4.98 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 400.00 Mn |
| Jun 30, 2026 | 7.62 Bn |
| Mar 31, 2026 | 6.88 Bn |
| Dec 31, 2025 | 11.44 Bn |
| Sep 30, 2025 | 9.56 Bn |
| Jun 30, 2025 | 6.66 Bn |
| Mar 31, 2025 | 7.07 Bn |
| Dec 31, 2024 | 11.46 Bn |
| Sep 30, 2024 | 13.61 Bn |
| Jun 30, 2024 | 7.90 Bn |
| Mar 31, 2024 | 9.47 Bn |
| Dec 31, 2023 | 13.39 Bn |
| Sep 30, 2023 | 12.41 Bn |
| Jun 30, 2023 | 10.89 Bn |
| Mar 31, 2023 | 12.00 Bn |
| Dec 31, 2022 | 7.52 Bn |
| Sep 30, 2022 | 8.73 Bn |
| Jun 30, 2022 | 3.63 Bn |
| Mar 31, 2022 | 13.85 Bn |
| Dec 31, 2021 | 12.41 Bn |
API Access
Novartis Ag Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=NVS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "NVS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=NVS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();